FDA Approves A New Class of Lipid-Lowering Drugs - PCSK9 Inhibitors - Ellen Dolgen

FDA Approves A New Class of Lipid-Lowering Drugs – PCSK9 Inhibitors

Heart Health News!! One out of three American adults is estimated to have high LDL cholesterol, according to the Centers for Disease Control and Prevention. Elevated LDL cholesterol is recognized as a major risk factor for cardiovascular disease, which remains the leading cause of death worldwide.   In the United States, 1 in 4 women dies from heart disease.

The FDA granted marketing approval on Thursday to evolocumab (Repatha), the second in a new class of lipid-lowering drugs — PCSK9 inhibitors. These drugs appear to sharply reduce levels of bad (LDL) cholesterol. Clinical trials of PCSK9 inhibitor drugs developed by Amgen, Sanofi and Regeneron demonstrate LDL levels are reduced by 60%. By comparison, statins — the current class of drugs that are the mainstay of treatment for high LDL — generally reduce LDL levels by 30-50%.

At this point, these new drugs appear to be quite costly.  However, it is always good to know the latest options available so that you and your healthcare professional can develop the best plan of action for your individual heart health needs.


Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Latest Updates


No spam, notifications only about new products, updates.

Social Media


On Key

Related Posts

Menopausal Brain Fog Ellen Dolgen.com

Warning Signs of Dementia

There is a big difference between dementia and the occasional mists of brain fog during perimenopause and menopause.

Menopause Barbie Ellen Dolgen

Introducing Menopause Barbie

Meet Menopause Barbie: not your typical doll. Shaped by wise women, she embodies strength, confidence, and embracing change.

Scroll to Top

If you want to educate your employees, colleagues, or friends about menopause, look no further!

Share via
Copy link